OncoMatch/Clinical Trials/NCT03897543
ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma
Is NCT03897543 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies ABX196 for carcinoma, hepatocellular.
Treatment: ABX196 — Open-label, uncontrolled, phase 1-2 study to evaluate the safety, tolerability, pharmacodynamic effects, and preliminary efficacy of ABX196 administered in combination with nivolumab in patients with hepatocellular carcinoma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — HCC
Patients with at least one prior systemic therapy for HCC
Cannot have received: tyrosine kinase inhibitor
Patients with tyrosine kinase inhibitor treatment within 2 weeks of first study dose
Cannot have received: locoregional therapy
Patients with previous locoregional therapy or major surgery to the liver within 6 weeks before first study dose
Cannot have received: surgery
Patients with minor surgery to liver or another site within 1 week before first study dose
Lab requirements
Liver function
Child-Pugh class A liver score within 7 days of first study dose; no history of hepatic encephalopathy; no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control (patients with ascites only on radiographic imaging are eligible)
Child-Pugh class A liver score within 7 days of first study dose; no history of hepatic encephalopathy; no prior or current clinically significant ascites as measured by physical examination and that requires active paracentesis for control
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Scripps Clinic Torrey Pines · La Jolla, California
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03897543 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior tyrosine kinase inhibitor, locoregional therapy, surgery disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages